In a real-world clinical setting, obese women with PCOS lost an average of 11.4% of their body weight on semaglutide, with significant improvements in blood pressure, blood sugar, cholesterol, and menstrual regularity.
11.4% body weight lostObese women with PCOS lost an average of 12.6 kg on semaglutide — well above the 5% threshold that guidelines say meaningfully improves PCOS outcomes.
What the researchers found
Across 58 obese women with PCOS treated with semaglutide in routine clinical practice, mean weight loss was 12.6 ± 9.6 kg, representing 11.4% of total body weight (p < 0.0001). Seventy-nine percent of participants lost more than 5% of their body weight — the threshold considered clinically meaningful for PCOS.
Mean BMI dropped from 40.7 to 36.2 kg/m² (p < 0.0001). Systolic blood pressure fell by 6.3 mmHg (p = 0.012). HbA1c decreased from 35.3 to 33 mmol/mol (p = 0.0014). Total cholesterol dropped from 4.8 to 4.45 mmol/L (p = 0.03). Among those with irregular periods, 50% reported subjective improvement, while 33% with acne and 29% with hirsutism also noted improvements.
Why it matters
Clinical guidelines suggest GLP-1 receptor agonists could help women with PCOS, but they've noted a lack of evidence. This study fills part of that gap with real-world data showing semaglutide delivers substantial weight loss and metabolic improvements in this specific population — well beyond the 5% weight loss threshold known to improve PCOS outcomes.
The numbers in context
n=58; 12.6 kg mean weight loss (11.4%); BMI 40.7→36.2; SBP -6.3mmHg; HbA1c 35.3→33 mmol/mol; 79% lost >5% body weight; 50% improved menstrual cycles
How the study worked
This was a retrospective review of medical records from 58 women with both PCOS and obesity who were attending reproductive endocrinology clinics and had been prescribed semaglutide for at least 6 months. The researchers collected data on weight, BMI, blood pressure, HbA1c, cholesterol, and self-reported changes in menstrual regularity, acne, and excess hair growth before and after treatment.
Who was studied
Obese women with PCOS (mean age 34.7, mean BMI 40.7)
What this study cannot tell us
This was a retrospective study with no control group, so the improvements can't be definitively attributed to semaglutide alone. Menstrual, acne, and hirsutism improvements were based on subjective patient reports rather than objective measurements. The study was conducted at a single center in Ireland. The sample size of 58 is relatively small, and there was considerable variation in individual weight loss responses (standard deviation of 9.6 kg).
How to read the evidence
Rated moderate: real-world clinical data from a defined patient population with statistically significant results across multiple outcomes. However, the retrospective design, lack of control group, small sample size, and subjective symptom reporting limit the strength of causal conclusions.
When this study was published
Published in 2026 in the Irish Journal of Medical Science. This is very current research addressing an active gap in the evidence base for GLP-1 agonists in PCOS.
The bigger picture
PCOS affects up to 13% of women of reproductive age, and obesity worsens nearly every aspect of the syndrome — from metabolic risk to fertility to androgen symptoms. While semaglutide is well-studied for obesity and diabetes, evidence specifically in PCOS has been limited. This study adds to a growing body of real-world data suggesting that GLP-1 agonists may be particularly well-suited for this population, addressing both the metabolic and reproductive dimensions of the syndrome.
Questions still open
- Would a randomized controlled trial confirm these metabolic and reproductive benefits of semaglutide specifically in PCOS?
- Does the weight loss from semaglutide in PCOS translate to improved fertility outcomes?
- How do the benefits compare in women with PCOS who have lower BMIs versus the severely obese population studied here?
Common questions
Can semaglutide help with PCOS symptoms beyond weight loss?
How much weight did PCOS patients lose on semaglutide compared to general obesity studies?
Read the original research
The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.
Irish journal of medical science, 195(1), 131-136
Citation
Alawami, Fatimah; Novaes, Olivia; Gibney, James; Phelan, Niamh; Behan, Lucy Ann; Owens, Lisa. (2026). The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.. Irish journal of medical science, 195(1), 131-136. https://doi.org/10.1007/s11845-025-04194-x